Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
- - • Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3 - • Tzield is the first disease-modifying therapy for children...